BriaCell Therapeutics recently closed an $8.5 million stock sale after its positive results from mid-stage testing of its experimental metastatic breast cancer therapy, writes John George for the Philadelphia Business Journal.

The company announced it sold 12,325,000 common shares at 69 cents per share.

It was on September 11 that BriaCell announced the positive overall results related to survival and progression-free survival rates from its Phase 2 clinical study of its new drug candidate, Bria-IMT. It was used in combination with an immune check point inhibitor in 54 late-stage metastatic breast cancer patients.

“Overall survival in patients with heavily pre-treated metastatic breast cancer is very poor,” said Dr. Sara A. Hurvitz, a professor of medicine at Fred Hutch Cancer Center and University of Washington and a BriaCell medical advisory board member, in a statement. “The BriaCell early data is quite encouraging from both efficacy and tolerability standpoints.”

BriaCell as a company believes its Bria-IMT regimen could have a meaningful impact in the lives of heavily pre-treated metastatic breast cancer patients.

“We look forward to further clinical development of Bria-IMT with the goal of establishing it as a new standard of care for patients with metastatic breast cancer,” BriaCell CEO William V. Williams said.

Read more about BriaCell and its new cancer therapy drug candidate in the Philadelphia Business Journal.

_____